PCM
AXSM icon

Palisade Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Palisade Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.15M Sell
25,138
-15,425
-38% -$3.35M 0.27% 115
2026
Q1 		$6.86M Buy
+40,563
New +$7.01M 0.23% 126

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Palisade Capital Management's AXSM Position: Q2 2026 in Review

Palisade Capital Management reduced its Axsome Therapeutics (AXSM) stake by 38% in Q2 2026, selling an estimated $3.35M and leaving 25,138 shares worth $6.15M. The position accounts for 0.27% of the portfolio, ranked #115.

Palisade Capital Management first reported a position in AXSM in Q1 2026 and has held it in 2 quarters since. The position peaked at $6.86M in Q1 2026. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Palisade Capital Management held 25,138 shares of Axsome Therapeutics worth $6.15M as of Q2 2026.
  • Palisade Capital Management sold 15,425 Axsome Therapeutics shares in Q2 2026, an estimated $3.35M.
  • Axsome Therapeutics made up 0.27% of Palisade Capital Management's portfolio in Q2 2026, its #115 holding.
  • Palisade Capital Management first reported a position in Axsome Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Palisade Capital Management's Axsome Therapeutics position peaked at $6.86M in Q1 2026.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Palisade Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.